|

Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated with Percutaneous Coronary Intervention

RECRUITINGN/ASponsored by Odense University Hospital
Actively Recruiting
PhaseN/A
SponsorOdense University Hospital
Started2024-11-16
Est. completion2028-07-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06692140

Summary

The objective of this randomized study is to compare the safety and efficacy of the ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent to the everolimus-eluting family stents (durable polymer everolimus-eluting Xience or Promus stents) in a population-based setting with coronary artery stenosis treated with percutaneous coronary intervention

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* All patients aged ≥18 years who are eligible for treatment with one or several drug-eluting coronary stents

Exclusion Criteria:

* Age \< 18 years
* Not able to consent to study participating (eg. intubated patients)
* Unstable circuit or in cardiogenic shock and therefore not able to understand the information and purpose of the study
* Do not speak Danish
* Already included in the SORT OUT XII study
* Life expectancy \<1 year
* Allergic to study related treatment

Conditions4

Coronary Artery DiseaseHeart DiseaseIschemia, MyocardialPercutaneous Coronary Intervention (PCI)

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.